文献速递腹部技术与安全PETCT

使用FDG-PET/CT的改良腹膜癌指数(PET-PCI)预测腹膜假黏液瘤患者肿瘤分级和无进展生存期的价值

Impact of a modified peritoneal cancer index using FDG-PET/CT (PET-PCI) in predicting tumor grade and progression-free survival in patients with pseudomyxoma peritonei.
PubMed 文献 · Eur Radiol · 2019-03-14

本研究纳入35例在细胞减灭术和/或腹腔热灌注化疗前接受18F-FDG-PET/CT的腹膜假黏液瘤患者,评估基于13个腹盆腔区域视觉评分之和的改良PET-PCI对病理分级和无进展生存期的预测价值。结果显示高分级组PET-PCI和SUVmax均显著高于低分级组,PET-PCI以12为界值时高低两组无进展生存期差异有统计学意义(HR 12.4),SUVmax最佳界值为2.7(HR 4.7),多因素Cox回归中PET-PCI与无进展生存期独立且显著相关。

要点

  • PET-PCI通过13个腹盆腔区域FDG摄取视觉评分求和获得,摄取评分0–3分。
  • 高分级腹膜假黏液瘤患者PET-PCI和SUVmax均显著高于低分级患者。
  • PET-PCI以12为界值时高低两组无进展生存期差异有统计学意义(HR 12.4)。

核心结论

  • PET-PCI可反映组织病理学特征,似乎有助于预测腹膜假黏液瘤患者的复发。

研究设计与样本

  • 研究纳入35例在细胞减灭术和/或腹腔热灌注化疗前接受18F-FDG-PET/CT的患者,PET-PCI由13个特定腹盆腔区域腹膜假黏液瘤病灶的视觉FDG摄取评分求和确定,同时评估病灶SUVmax。

关键影像表现/征象

  • 摄取评分定义为0分无病灶或病灶无摄取,1分轻度摄取低于或等于纵隔血池,2分中度摄取高于纵隔但低于或等于肝脏,3分浓密摄取中度至明显高于肝脏。
  • 病理诊断显示19例低分级腹膜假黏液瘤和16例高分级腹膜假黏液瘤。
  • 高分级腹膜假黏液瘤患者PET-PCI和SUVmax显著高于低分级患者(PET-PCI 14.8 vs. 8.7,p=0.007;SUVmax 3.6 vs. 2.6,p=0.013)。

诊断标准与关键数值

  • PET-PCI以12为界值时,Kaplan-Meier分析显示高PET-PCI与低PET-PCI患者无进展生存期差异有统计学意义(p<0.001;风险比HR 12.4)。
  • SUVmax最佳界值为2.7,与无进展生存期的相关性亦有统计学意义(p=0.008;HR 4.7)。
  • 多因素Cox比例风险回归中,PET-PCI与无进展生存期独立且显著相关。

临床应用与阅片要点

  • PET-PCI在预测无进展生存期方面提供高于SUVmax的预后效能。
  • PET-PCI与腹膜假黏液瘤组织病理学分级高度相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The peritoneal cancer index (PCI) is widely used for assessing pseudomyxoma peritonei (PMP) in surgery. The aim of this study was to evaluate the utility of a modified PCI using 18F-fluorodeoxyglucose (18F-FDG)-PET/CT (PET-PCI) for predicting pathologic grade and progression-free survival (PFS) in patients with PMP.

METHODS: Thirty-five patients who underwent 18F-FDG-PET/CT before cytoreductive surgery and/or hyperthermic intraperitoneal chemotherapy were enrolled. PET-PCI was determined by summing up the visually scored 18F-FDG uptake of PMP lesions in 13 specific abdominal-pelvic regions. Uptake score was defined as 0, no lesion or lesion without uptake; 1, slight uptake less than or equivalent to mediastinal blood pool; 2, moderate uptake above mediastinal but below or equal to liver; and 3, intense uptake moderately to markedly higher than liver. SUVmax of the lesion was also evaluated.

RESULTS: Pathologic diagnosis revealed 19 patients with low-grade PMP and 16 patients with high-grade PMP. Patients with high-grade PMP showed significantly higher PET-PCI and SUVmax than patients with low-grade PMP (PET-PCI 14.8 vs. 8.7, p = 0.007; SUVmax 3.6 vs. 2.6, p = 0.013). Using a cutoff PET-PCI of 12, Kaplan-Meier analyses showed a significant difference in PFS between patients with high and low PET-PCI (p < 0.001; hazard ratio (HR), 12.4). For SUVmax, the optimal cutoff was 2.7 and the correlation with PFS was also significant (p = 0.008; HR, 4.7). In multivariate Cox proportional-hazards regression, PET-PCI was independently and significantly correlated with PFS.

CONCLUSIONS: PET-PCI can reflect histopathologic features and appears useful for predicting recurrence in patients with PMP.

KEY POINTS: • Peritoneal cancer index using 18F-FDG-PET/CT (PET-PCI) has great potential for predicting progression-free survival in patients with pseudomyxoma peritonei. • PET-PCI provides higher prognostic performance than maximum standardized uptake value (SUVmax). • PET-PCI shows high correlation with histopathologic grade of pseudomyxoma peritonei.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Hotta M, Minamimoto R, Gohda Y, et al. Impact of a modified peritoneal cancer index using FDG-PET/CT (PET-PCI) in predicting tumor grade and progression-free survival in patients with pseudomyxoma peritonei. Eur Radiol. 2019. PMID: 30874878. doi:10.1007/s00330-019-06102-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。